# Evaluation to Assess Safety and Tolerability of DM199 in Subjects With Acute Ischemic Stroke

> **NCT03290560** · PHASE2 · COMPLETED · sponsor: **DiaMedica Therapeutics Inc** · enrollment: 92 (actual)

## Conditions studied

- Acute Ischemic Stroke

## Interventions

- **DRUG:** Recombinant human tissue kallikrein
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03290560
- **Lead sponsor:** DiaMedica Therapeutics Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-19
- **Primary completion:** 2020-01-23
- **Final completion:** 2020-01-23
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2022-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03290560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03290560, "Evaluation to Assess Safety and Tolerability of DM199 in Subjects With Acute Ischemic Stroke". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03290560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*